Page 2 - Davidw Osborne News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Davidw osborne. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Davidw Osborne Today - Breaking & Trending Today

-$1.36 EPS Expected for Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) This Quarter

Brokerages expect Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Rating) to report ($1.36) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Arcutis Biotherapeutics’ earnings. The lowest EPS estimate is ($1.38) and the highest is ($1.34). Arcutis Biotherapeutics reported earnings of ($0.84) per share in the […] ....

Arcutis Biotherapeutic , Todd Franklin Watanabe , Arcutis Biotherapeutics , Davidw Osborne , Allspring Global Investments Holdings , Morgan Stanley , Securities Exchange Commission , Zacks Investment Research , Thrivent Financial For Lutherans , Indexiq Advisors , Arcutis Biotherapeutics Company Profile Get Rating , Cantor Fitzgerald , Goldman Sachs Group , Arcutis Biotherapeutics Inc , Get Rating , Investment Research , Franklin Watanabe , Exchange Commission , Global Investments Holdings , Capital Management , Nasdaq Arqt ,

Arcutis Biotherapeutics (NASDAQ:ARQT) Releases Earnings Results, Beats Expectations By $0.23 EPS

Arcutis Biotherapeutics (NASDAQ:ARQT – Get Rating) announced its quarterly earnings results on Thursday. The company reported ($1.27) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.50) by $0.23, MarketWatch Earnings reports. NASDAQ ARQT traded down $1.62 during trading hours on Friday, reaching $19.40. 385,075 shares of the company’s stock were exchanged, compared […] ....

United States , Todd Franklin Watanabe , Arcutis Biotherapeutics , Davidw Osborne , Morgan Stanley , Securities Exchange Commission , Zacks Investment Research , America Corp , Invesco Ltd , Guggenheim Capital , Cantor Fitzgerald , Cubist Systematic Strategies , Goldman Sachs Group , Royal Bank , Arcutis Biotherapeutics Inc , Get Rating , Marketwatch Earnings , Investment Research , Franklin Watanabe , Exchange Commission , Systematic Strategies , Nasdaq Arqt ,

Arcutis Biotherapeutics (NASDAQ:ARQT) Lifted to Hold at Zacks Investment Research

Arcutis Biotherapeutics (NASDAQ:ARQT – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Monday, Zacks.com reports. According to Zacks, “Arcutis Biotherapeutics Inc. is late-stage biopharmaceutical company. It is focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases. The […] ....

United States , Westlake Village , Arcutis Biotherapeutics , Davidw Osborne , Allspring Global Investments Holdings , Morgan Stanley , Zacks Investment Research , Thrivent Financial For Lutherans , Indexiq Advisors , Cantor Fitzgerald , Orbimed Advisors Llc , Goldman Sachs Group , Arcutis Biotherapeutics Inc , Get Rating , Global Investments Holdings , Capital Management , Nasdaq Arqt ,

Zacks Investment Research Downgrades Arcutis Biotherapeutics (NASDAQ:ARQT) to Sell

Arcutis Biotherapeutics (NASDAQ:ARQT – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Tuesday, Zacks.com reports. According to Zacks, “Arcutis Biotherapeutics Inc. is late-stage biopharmaceutical company. It is focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases. The company’s […] ....

United States , Westlake Village , Todd Franklin Watanabe , Zurcher Kantonalbank Zurich Cantonalbank , Arcutis Biotherapeutics , Davidw Osborne , Morgan Stanley , Zacks Investment Research , Thrivent Financial For Lutherans , Arcutis Biotherapeutics Company Profile Get Rating , Denali Advisors , Cantor Fitzgerald , Goldman Sachs Group , Penn Mutual Asset Management , Royal Bank , Arcutis Biotherapeutics Inc , Get Rating , Franklin Watanabe , Kantonalbank Zurich Cantonalbank , Mutual Asset Management , Thrivent Financial , Nasdaq Arqt ,

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Insider David W. Osborne Sells 2,197 Shares

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Rating) insider David W. Osborne sold 2,197 shares of the company’s stock in a transaction on Thursday, April 21st. The shares were sold at an average price of $20.42, for a total transaction of $44,862.74. Following the completion of the transaction, the insider now owns 257,229 shares in the […] ....

Thomson Reuter , Zurcher Kantonalbank Zurich Cantonalbank , Arcutis Biotherapeutics , Davidw Osborne , Morgan Stanley , Securities Exchange Commission , Zacks Investment Research , Norges Bank , Blackrock Inc , Alphacentric Advisors , Cantor Fitzgerald , Walleye Capital , Goldman Sachs Group , Arcutis Biotherapeutics Inc , Get Rating , Exchange Commission , Kantonalbank Zurich Cantonalbank , Centric Advisors , Investment Research , Nasdaq Arqt , Insider Trading , Nsider Trades ,